Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amitriptyline + gabapentin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amitriptyline + gabapentin is a fixed-dose combination of two pharmaceutical agents used primarily for the management of neuropathic pain. Amitriptyline is a tricyclic antidepressant that increases levels of serotonin and noradrenaline in the brain, thereby modulating pain signal transmission. Gabapentin is an anticonvulsant that binds to voltage-gated calcium channels in the central nervous system, reducing neuronal excitability and relieving nerve pain. The combination provides additive or synergistic analgesic effects, particularly beneficial in chronic neuropathic conditions such as diabetic neuropathy and chronic pelvic pain[2][4][5]. This combination may increase side effects like dizziness, drowsiness, confusion, and difficulty concentrating due to additive central nervous system depressant effects[1][3].
- Other names
- gabapentin + amitriptyline
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on amitriptyline + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amitriptyline + gabapentin.